

October 29, 2023

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai – 400 001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra – Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Company has received an order from the Transfer Pricing Officer being issued under section 92CA(3) of the Income Tax Act, 1961 for the assessment year 2021-22, wherein an adjustment on the legacy issues have been proposed. The estimated tax impact of the adjustments proposed is Rs. 9.17 crores (approx.). The said amount does not involve any interest or penal consequences. The company will suitably challenge the order in the due course.

In this regard, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking You

For AstraZeneca Pharma India Limited

Manasa. R
Company Secretary

Annexure – A

Sl. No.	Particulars	Details
1.	Name of the opposing party	The office of Deputy Commissioner of Income Tax, TP 1(1)(1), Bangalore.
2.	Brief details of dispute/litigation	Company has received an order from the Transfer Pricing Officer being issued under section 92CA(3) the Income Tax Act, 1961 for assessment year 2021-22, wherein an adjustment on the legacy issues has been proposed.
3.	Court/tribunal/agency where the litigation is filed	The matter will be challenged before appropriate appellate forum, once the draft order is received.
4.	Expected financial implications, if any, due to compensation, penalty etc.	Matter will be suitably challenged in due course; The expected overall financial implication cannot be determined at this stage.
5.	Quantum of claims, if any	Rs. 9.17 crores (approx.) excluding interest and penalty.